EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Reversion from HBeAg negative to HBeAg positive phenotype after interferon therapy for chronic hepatitis B



Reversion from HBeAg negative to HBeAg positive phenotype after interferon therapy for chronic hepatitis B



Hepatology 30(4 PART 2): 601A




(PDF emailed within 1 workday: $29.90)

Accession: 035666634

Download citation: RISBibTeXText



Related references

Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Journal of Medical Virology 89(1): 130-138, 2016

What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B. Current Hepatitis Reports 11(2): 65-69, 2012

Interferon therapy upon hbeag positive chronic hepatitis type b correlation between disappearance of hbeag and it's clinical features. Journal of the Iwate Medical Association 42(6): 941-956, 1990

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. Journal of Viral Hepatitis 14(11): 751-766, 2007

The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pakistan Journal of Pharmaceutical Sciences 28(4 Suppl): 1493-1497, 2015

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrobial Agents and ChemoTherapy 59(7): 4121-4128, 2016

Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study. Journal of Hepatology 64(2): S598-S599, 2016

An analysis of clinical features in HBeAg-negative and HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 15(6): 428-430, 2007

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur Journal of Microbiology 8(3): E21444-E21444, 2015

New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatology 41(6): 1402-1406, 2005

Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver International 30(8): 1115-1122, 2010

Histological Spectrum of Chronic Hepatitis in HBeAg Positive and HBeAg Negative Hepatitis B Virus Infection. Mymensingh Medical Journal 24(4): 679-683, 2016

Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B. Plos One 8(3): E58236-E58236, 2013

Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatology Research 46(10): 992-1001, 2015

Characteristic of liver pathology in HBeAg-positive and HBeAg-negative chronic hepatitis B patients with mildly elevated ALT. Zhonghua Gan Zang Bing Za Zhi 20(5): 348-352, 2012